3/19
12:14 pm
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $20.00 price target on the stock, up previously from $11.00.
Low
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $20.00 price target on the stock, up previously from $11.00.
3/19
12:14 pm
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $20.00 price target on the stock, up previously from $11.00.
Low
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $20.00 price target on the stock, up previously from $11.00.
3/19
08:04 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.50 price target on the stock.
Medium
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.50 price target on the stock.
3/19
07:36 am
trvi
Rating for TRVI
Medium
Report
Rating for TRVI
3/19
07:36 am
trvi
Rating for TRVI
Medium
Report
Rating for TRVI
3/11
09:57 am
trvi
Rating for TRVI
Medium
Report
Rating for TRVI
3/11
09:57 am
trvi
Rating for TRVI
Medium
Report
Rating for TRVI
3/10
09:07 am
trvi
Rating for TRVI
Medium
Report
Rating for TRVI
3/10
09:07 am
trvi
Rating for TRVI
Medium
Report
Rating for TRVI
3/10
08:08 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) was upgraded by analysts at Raymond James from an "outperform" rating to a "strong-buy" rating. They now have a $29.00 price target on the stock, up previously from $9.00.
Medium
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) was upgraded by analysts at Raymond James from an "outperform" rating to a "strong-buy" rating. They now have a $29.00 price target on the stock, up previously from $9.00.
3/10
08:08 am
trvi
Trevi Therapeutics, Inc. (NASDAQ: TRVI) was upgraded by analysts at Raymond James from an "outperform" rating to a "strong-buy" rating. They now have a $29.00 price target on the stock, up previously from $9.00.
Medium
Report
Trevi Therapeutics, Inc. (NASDAQ: TRVI) was upgraded by analysts at Raymond James from an "outperform" rating to a "strong-buy" rating. They now have a $29.00 price target on the stock, up previously from $9.00.
3/10
07:25 am
trvi
Trevi Therapeutics upgraded to Strong Buy from Outperform at Raymond James
Medium
Report
Trevi Therapeutics upgraded to Strong Buy from Outperform at Raymond James
3/10
07:25 am
trvi
Trevi Therapeutics upgraded to Strong Buy from Outperform at Raymond James
Medium
Report
Trevi Therapeutics upgraded to Strong Buy from Outperform at Raymond James
3/10
06:55 am
trvi
Rating for TRVI
High
Report
Rating for TRVI
3/10
06:55 am
trvi
Rating for TRVI
High
Report
Rating for TRVI